Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2199-2204

  Fourati, Slim ^a,b   Visseaux, Benoit ^c,d   Armenia, Daniele ^e   Morand Joubert, Laurence ^a,f,g   Artese, Anna ^h   Charpentier, Charlotte ^c,d   Eede, Peter Van Den ⁱ   Costa, Giosuè ^h   Alcaro, Stefano ^h   Wirden, Marc ^a,b   Perno, Carlo Federico ^j   Silberstein, Francesca Ceccherini ^e   Descamps, Diane ^c,d   Calvez, Vincent ^a,b,g   Marcelin, Anne Genevieve ^a,b,g  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f HÔPITAL SAINT ANTOINE   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

more..

Author keywords

Drug resistance; HIV; Nucleoside analogues

Indexed keywords

ABACAVIR; ASPARAGINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CODON; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; SEQUENCE DATABASE; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; WILD TYPE;

DRUG RESISTANCE; HIV; NUCLEOSIDE ANALOGUES;

HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR DOCKING SIMULATION; MUTATION, MISSENSE; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD; VIRUS REPLICATION;

EID: 84888815823     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt200     Document Type: Article

References (21)

1. Margot NA, Isaacson E, McGowan I et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227-35.
2. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-63.
3. Roge BT, Katzenstein TL, Obel N et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antiviral Therapy 2003; 8: 173-82.
4. Sharma PL, Nurpeisov V, Hernandez-Santiago B et al. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004; 4: 895-919.
5. Huang H, Chopra R, Verdine GL et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-75.
6. Hoogewerf M, Regez RM, Schouten WE et al. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362: 1979-80.
7. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292: 180-9.
8. Ross LL, Dretler R, Gerondelis P et al. A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine. AIDS 2006; 20: 787-9.
9. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008; 10: 67-84.
10. Svicher V, Alteri C, Artese A et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010; 55: 336-44.
11. McDonald DQ, Still W.C. AMBER torsional parameters for the peptide backbone. Tetrahedron Lett 1992; 33: 7743-6.
12. Still WC, Tempczyk A, Hawley RC et al. Semianalytical treatment of solvation for molecular mechanism and dynamics. J Am Chem Soc 1990; 112: 6127-9.
13. Mohamadi F, Richards NGJ, Guida WC. et al. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 2004; 11: 440-67.
14. Morris GM, Goodsell DS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free-energy function. J Comput Chem 1998; 19: 1639-62.
15. Coleman RS, Woodward RL, Hayes AM et al. Dependence of DNA sequence selectivity and cell cytotoxicity on azinomycin A and B epoxyamide stereochemistry. Org Lett 2007; 9: 1891-4.
16. Parikh UM, Bacheler L, Koontz D et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971-7.
17. Parikh UM, Barnas DC, Faruki H et al. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194: 651-60.
18. Wirden M, Malet I, Derache A et al. Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. AIDS 2005; 19: 630-2.
19. Sluis-Cremer N, Arion D, Kaushik N et al. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem J 2000; 348 Pt 1: 77-82.
20. De Mendoza C, Jimenez-Nacher I, Garrido C et al. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. Clin Infect Dis 2008; 46: 1782-5.
21. Miller MD, Haddad M, Su C et al. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010. Antivir Ther 2012; 17: 993-9.